Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
256
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

257
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
257

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Quantitative ultrasound for hepatic fat assessment: physical principles, signal processing, and technological advances - a scoping review.

Biomedical physics & engineering express·2026
Same author

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same author

Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis.

The lancet. Gastroenterology & hepatology·2026
Same author

Agile 3+ and Agile 4 scores are accurate to detect advanced metabolic dysfunction-associated steatotic liver disease.

European journal of gastroenterology & hepatology·2026
Same author

Name MASLD/MASH - and act on it.

JHEP reports : innovation in hepatology·2026

相关实验视频

Updated: Sep 10, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K

在MASLD患者中长期使用pioglitazone:多中心初步研究的见解

Isabel Veloso Alves Pereira1, Ana Beatriz Souza de Oliveira1, Patricia Momoyo Yoshimura Zitelli1

  • 1Divisão de Gastroenterologia e Hepatologia, Hospital das Clínicas HCFMUSP (LIM-07), Departamento de Gastroenterologia e Nutrologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Clinics (Sao Paulo, Brazil)
|August 22, 2025
PubMed
概括
此摘要是机器生成的。

长期治疗皮奥格利塔可显著改善与代谢功能失调相关的脂肪酸性肝病 (MASLD) 患者的肝酶和脂肪酸症. 这表明pioglitazone是一种有价值的治疗选择,特别是当替代品有限时.

关键词:
美国美国皮奥格利塔

更多相关视频

Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC
06:28

Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC

Published on: February 13, 2020

19.4K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.1K

相关实验视频

Last Updated: Sep 10, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K
Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC
06:28

Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC

Published on: February 13, 2020

19.4K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.1K

科学领域:

  • 肝病学
  • 代谢疾病
  • 药理学

背景情况:

  • 代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个越来越严重的健康问题.
  • 非侵入性生物标志物对于评估MASLD肝脏健康至关重要.
  • 需要进一步研究pioglitazone对MASLD的长期治疗效应.

研究的目的:

  • 评估皮奥格利塔对MASLD患者肝硬性,肥胖症和其他非侵入性生物标志物的长期影响.
  • 评估皮奥格利塔在不同治疗时间 (1-3年与4-10年) 的疗效.

主要方法:

  • 在65名接受pioglitazone (30- 45毫克/ 天) 治疗的MASLD患者中进行了多中心的回顾性研究.
  • 在治疗前和治疗后评估振动控制过渡弹性图 (VCTE),控制衰减参数 (CAP) 和纤维扫描AST得分.
  • 根据治疗时间分为两组:1-3年和4-10年.

主要成果:

  • 在两组中都观察到氨酸转移酶 (ALT) 和胺转移酶 (GGT) 的显著降低.
  • 在4至10岁的组中,CAP显著下降,表明肝脏肥胖症有所减少.
  • 在两个治疗持续时间组中,FASTTM评分的改善显著.

结论:

  • 在MASLD患者中,长期治疗皮奥格利塔显著的代谢和肝脏效益.
  • 皮奥格利塔是一种具有成本效益和可获得的MASLD治疗方法.
  • 这些发现支持皮奥格利塔在MASLD管理中的作用,特别是在资源有限的环境中.